Published in Nature on December 21, 2006
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
Tumor angiogenesis. N Engl J Med (2008) 11.30
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A (2007) 4.27
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol (2011) 3.25
Chronic DLL4 blockade induces vascular neoplasms. Nature (2010) 3.14
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology (2011) 2.94
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
The many facets of Notch ligands. Oncogene (2008) 2.57
Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad Sci U S A (2008) 2.55
Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer (2010) 2.51
Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature (2014) 2.42
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol (2010) 2.37
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood (2009) 2.29
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol (2008) 2.18
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature (2012) 2.13
Identification and functional analysis of endothelial tip cell-enriched genes. Blood (2010) 2.02
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther (2013) 1.96
Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene (2008) 1.95
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. J Clin Invest (2012) 1.87
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell (2014) 1.83
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol (2008) 1.82
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood (2009) 1.81
A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res (2008) 1.80
Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest (2008) 1.76
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest (2009) 1.68
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
VEGF and endothelial guidance in angiogenic sprouting. Organogenesis (2008) 1.63
Canonical and non-canonical Notch ligands. Curr Top Dev Biol (2010) 1.62
Notch signaling in the vasculature. Curr Top Dev Biol (2010) 1.62
Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res (2011) 1.58
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res (2009) 1.57
Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 1.55
VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer (2008) 1.55
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54
Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev Cell (2012) 1.53
Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest (2011) 1.51
The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis (2013) 1.50
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J Clin Invest (2012) 1.50
Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol (2010) 1.49
Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med (2009) 1.48
Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood (2008) 1.47
Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development (2008) 1.43
Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol (2009) 1.43
Fellow travellers: emergent properties of collective cell migration. EMBO Rep (2012) 1.41
Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol (2008) 1.41
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One (2010) 1.41
Tipping the balance: robustness of tip cell selection, migration and fusion in angiogenesis. PLoS Comput Biol (2009) 1.40
The functional role of Notch signaling in human gliomas. Neuro Oncol (2009) 1.39
Mechanisms of glioma-associated neovascularization. Am J Pathol (2012) 1.39
Delta-like 4/Notch signaling promotes Apc (Min/+) tumor initiation through angiogenic and non-angiogenic related mechanisms. BMC Cancer (2017) 1.38
VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med (2013) 1.38
Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol (2007) 1.36
Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol (2011) 1.36
Involvement of notch signaling in wound healing. PLoS One (2007) 1.35
EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood (2011) 1.33
Griffonia simplicifolia isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouse. J Comp Neurol (2008) 1.32
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31
Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One (2008) 1.31
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia (2009) 1.27
Perivascular instruction of cell genesis and fate in the adult brain. Nat Neurosci (2011) 1.27
Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest (2013) 1.27
Lymphangiogenic factors, mechanisms, and applications. J Clin Invest (2014) 1.27
Notch receptor-ligand binding and activation: insights from molecular studies. Semin Cell Dev Biol (2012) 1.26
Multiscale models of angiogenesis. IEEE Eng Med Biol Mag (2009) 1.26
Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A (2012) 1.26
Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol (2015) 1.24
Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J (2007) 1.24
Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther (2013) 1.23
Angiogenesis as a therapeutic target in malignant gliomas. Oncologist (2009) 1.23
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med (2013) 1.23
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer (2009) 1.22
The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J Biol Chem (2008) 1.22
The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol (2014) 1.22
Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med (2012) 1.21
Regulation of endothelial cell differentiation and specification. Circ Res (2013) 1.20
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell (2011) 1.20
Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol (2012) 1.20
Intrinsic selectivity of Notch 1 for Delta-like 4 over Delta-like 1. J Biol Chem (2013) 1.19
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst (2008) 1.18
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol (2010) 1.17
Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res (2012) 1.17
Novel insights into the differential functions of Notch ligands in vascular formation. J Angiogenes Res (2009) 1.16
Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med (2012) 8.24
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
The knockout mouse project. Nat Genet (2004) 7.80
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell (2004) 7.60
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol (2003) 7.47
SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 6.79
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol (2005) 5.56
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med (2006) 5.49
Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 5.29
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A (2004) 4.06
Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol (2010) 3.61
Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest (2004) 3.53
The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood (2004) 3.50
Ephrin-B2 and EphB1 mediate retinal axon divergence at the optic chiasm. Neuron (2003) 3.39
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med (2002) 3.36
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol (2005) 3.28
Lhx6 delineates a pathway mediating innate reproductive behaviors from the amygdala to the hypothalamus. Neuron (2005) 3.21
Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med (2005) 3.18
Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol (2008) 3.15
RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology (2008) 3.13
F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol (2006) 3.13
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol (2002) 2.96
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer (2007) 2.96
Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A (2005) 2.77
Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metab (2005) 2.75
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med (2010) 2.75
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol (2006) 2.74
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med (2006) 2.67
Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife (2013) 2.66
Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol (2004) 2.58
Alternatively activated macrophage-derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. J Exp Med (2009) 2.51
Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol (2007) 2.50
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am J Physiol Heart Circ Physiol (2005) 2.34
Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev (2004) 2.32
Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem (2004) 2.32
Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest (2002) 2.26
Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A (2004) 2.23
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell (2009) 2.17
Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci U S A (2010) 2.06
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res (2003) 2.06
Deletion of Notch1 converts pro-T cells to dendritic cells and promotes thymic B cells by cell-extrinsic and cell-intrinsic mechanisms. Immunity (2008) 2.05
Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A (2006) 2.03
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood (2003) 2.03
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A (2003) 1.82
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med (2014) 1.82
Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol (2006) 1.79
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.78
Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther (2008) 1.77
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol (2006) 1.72
Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood (2005) 1.71
Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. Kidney Int (2008) 1.70
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
Loss-of-function analysis of EphA receptors in retinotectal mapping. J Neurosci (2004) 1.67
Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol (2003) 1.63
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res (2007) 1.60
EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J (2002) 1.58
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res (2009) 1.58
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem (2001) 1.51
Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc Natl Acad Sci U S A (2011) 1.51
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res (2012) 1.50
Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J (2013) 1.47